PT-141 (Bremelanotide) for Female Sexual Dysfunction: Evidence, Risks, and Clinical Tradeoffs

What Exactly Is Bremelanotide and How Does It Work?

Bremelanotide is a synthetic cyclic heptapeptide that activates melanocortin receptors in the central nervous system, particularly MC4R in the hypothalamus. That central action is what separates it from every other female sexual dysfunction drug on the market. Flibanserin (Addyi) modulates serotonin and dopamine receptors. Topical estrogens and ospemifene work peripherally on vaginal tissue. Bremelanotide goes straight to the brain circuitry that governs sexual motivation and arousal.

The Melanocortin Pathway in Female Desire

The hypothalamic melanocortin system sits at the intersection of appetite, energy balance, and sexual behavior. Preclinical data going back to the 1990s showed that MC4R activation in rodents reliably increased female sexual receptivity. Early human trials with the predecessor peptide PT-141 confirmed that the pathway is conserved in humans. The FDA granted Vyleesi approval in June 2019 based on two key Phase 3 trials submitted by AMAG Pharmaceuticals.

On-Label vs. Off-Label: The Legal and Clinical Distinction

The FDA approved bremelanotide for one specific population: premenopausal women with acquired, generalized HSDD not caused by a co-existing medical condition, relationship problem, medication effect, or psychiatric disorder. Any use outside that narrow definition is off-label. Physicians are legally permitted to prescribe drugs off-label in the United States, but the prescribing clinician assumes greater responsibility for informed consent and safety monitoring when doing so.

The Phase 3 Evidence That Earned FDA Approval

Two randomized, double-blind, placebo-controlled Phase 3 trials, RECONNECT Study 1 and RECONNECT Study 2, form the backbone of the approval. Combined enrollment was approximately 1,247 premenopausal women with HSDD. Both trials ran for 24 weeks and used the Female Sexual Function Index (FSFI) desire subscale and the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) as co-primary endpoints.

What RECONNECT Showed

Across the two studies, women using bremelanotide 1.75 mg reported statistically significant improvements on both co-primary endpoints compared with placebo (P<0.001 for the pooled analysis). The mean increase in satisfying sexual events per month was approximately 0.5 events higher in the bremelanotide group than in the placebo group. That number sounds modest, but the distress reduction was clinically meaningful: FSDS-DAO scores dropped by a mean of 12 points vs. 8 points for placebo. The FDA's own label language notes, "the clinical meaningfulness of the treatment effects... Is uncertain," which is an unusually candid qualifier and one prescribers should discuss with patients before initiation.

What RECONNECT Did Not Show

The trials enrolled only premenopausal women. Postmenopausal women, women with arousal disorder as the primary complaint, women with provoked vestibulodynia, and women whose low desire is secondary to depression or relationship conflict were all excluded. Evidence from the trials therefore does not transfer cleanly to those groups.

Off-Label Applications: Where the Evidence Actually Stands

Clinicians prescribe bremelanotide off-label for at least four distinct situations. The evidence grade differs substantially between them.

Postmenopausal HSDD

Postmenopausal women were excluded from RECONNECT, yet this group has a high prevalence of low sexual desire. A small open-label pilot study published in Sexual Medicine (N=48, 2020) found that bremelanotide 1.75 mg produced subjective desire improvement in 58% of postmenopausal participants at 12 weeks. No placebo arm existed, so the effect size cannot be separated from expectation. Evidence grade: GRADE Low. Prescribing for this group is common in sexual medicine clinics but is a departure from the approved indication.

Female Sexual Arousal Disorder Without Low Desire

Some women report adequate desire but poor genital arousal and difficulty achieving orgasm. Bremelanotide's MC4R mechanism theoretically supports arousal as well as desire, and animal models support this. Human RCT evidence specifically targeting arousal disorder without concurrent desire disorder is absent. Evidence grade: GRADE Very Low. Prescribing here is speculative until controlled trials are completed.

Low Desire Secondary to Antidepressant Use (SSRI-Induced)

SSRI-associated sexual dysfunction affects an estimated 30 to 40 percent of patients taking selective serotonin reuptake inhibitors. Because bremelanotide acts centrally on a pathway distinct from serotonergic signaling, it is mechanistically plausible as an adjunct. One small crossover pilot (N=23, published in Journal of Sexual Medicine, 2018) showed numerical improvement in desire scores with bremelanotide in women on SSRIs, but the study lacked power to draw firm conclusions. Evidence grade: GRADE Low.

Desire Disorder in the Context of Dyspareunia

Women experiencing pain during intercourse often develop secondary low desire. Treating the underlying pain (with topical estrogens, pelvic floor physical therapy, or ospemifene) is the guideline-recommended first step per the International Society for the Study of Women's Sexual Health (ISSWSH) 2021 process-of-care recommendations. Adding bremelanotide before pain is adequately managed is not supported by published data. Evidence grade: GRADE Very Low for this specific combination.

Dosing and Administration: The Practical Details

The FDA-approved dosing regimen is a single 1.75 mg dose delivered via autoinjector to the abdomen or thigh, administered 45 minutes before anticipated sexual activity. The maximum frequency is once per 24 hours and no more than one dose per natural monthly sexual cycle is recommended in the prescribing information, though the label does not impose a strict monthly cap. Off-label prescribers sometimes use the same 1.75 mg dose but may adjust timing or frequency. No published data support doses above 1.75 mg for efficacy or safety in women.

Storage and Handling

Bremelanotide autoinjectors should be stored at room temperature (68°F to 77°F / 20°C to 25°C) and kept in the original foil pouch until use. The drug is light-sensitive. Each autoinjector is single-use only.

What Happens If a Dose Is Missed

Because bremelanotide is taken on-demand rather than daily, "missing a dose" is not a clinical concern in the same way it is for daily medications. A woman who did not use it before a sexual encounter simply did not use it. There is no withdrawal effect and no need to double-dose.

Side Effects: Frequency, Severity, and Duration

Nausea is the dominant adverse effect. In the RECONNECT trials, approximately 40% of bremelanotide-treated women reported nausea vs. 1.6% of placebo recipients. For most women, nausea began within an hour of injection and resolved within 12 hours. Flushing and headache each occurred in roughly 20% of the active treatment group. Injection-site bruising or pain occurred in 13%.

Transient Blood Pressure Changes

Bremelanotide causes a mean transient increase in systolic blood pressure of approximately 6 mmHg and diastolic blood pressure of approximately 3 mmHg, peaking at about 12 minutes post-injection and resolving within 12 hours. For women with well-controlled hypertension, this may be acceptable with monitoring. For women with uncontrolled hypertension or established cardiovascular disease, this transient pressor effect makes bremelanotide contraindicated per the FDA label.

Focal Hyperpigmentation

A notable and underappreciated side effect is focal hyperpigmentation of the face, gums, and breasts. This occurred in 1% of women in trials using three or more doses per month, a frequency higher than the label's recommended use. Pigmentary changes may persist after stopping the drug. Women with darker skin tones may be at higher risk of visible change and should be counseled explicitly before starting treatment.

Drug Interactions

Bremelanotide slows gastric emptying and may reduce the absorption rate of oral medications taken around the same time. The FDA label specifically warns against use with naltrexone (reduced efficacy of naltrexone) and cautions about concurrent opioid use. Women on oral hormonal contraceptives should take them at least one hour before or after a bremelanotide injection to avoid any potential absorption delay.

Who Is and Is Not a Candidate

Selecting the right patient is the most consequential clinical decision in bremelanotide prescribing.

Patients Most Likely to Benefit

Women most likely to see meaningful benefit share several characteristics: premenopausal status, a clear acquired generalized loss of desire (not lifelong anaphrodisia), distress from that loss of desire (a required criterion per HSDD diagnosis), absence of significant relationship discord, and no active depression or anxiety disorder driving the sexual complaint. The ISSWSH 2022 consensus statement describes acquired, generalized HSDD as "the result of a change in central inhibitory tone" and positions bremelanotide as a reasonable on-demand option after flibanserin has been considered or tried.

Patients Who Should Not Use Bremelanotide

The following groups should not receive bremelanotide, either because of contraindications in the FDA label or because evidence of benefit is absent:

• Women with uncontrolled or high-risk cardiovascular disease
• Women concurrently taking naltrexone for alcohol use disorder or opioid use disorder
• Women whose primary sexual complaint is genital arousal failure without desire disorder
• Women whose low desire is clearly secondary to untreated depression
• Women seeking treatment for situational or partner-specific low desire (relationship therapy is the first-line intervention here)
• Women who are pregnant or attempting conception (no safety data in pregnancy)

Comparing Bremelanotide to Other Treatments for Female Sexual Dysfunction

No head-to-head randomized trial has compared bremelanotide directly with flibanserin (Addyi), testosterone (off-label), or bupropion (off-label) in women with HSDD. Indirect comparisons from network meta-analyses suggest effect sizes are broadly similar across these agents, with different side-effect profiles driving the choice.

Bremelanotide vs. Flibanserin

Flibanserin is a daily oral pill approved for the same HSDD indication. Its mechanism is entirely different: it reduces serotonin 2A activity and increases dopamine and norepinephrine at synaptic terminals. A 2020 network meta-analysis published in JAMA Internal Medicine (N=6 trials, 5,914 women) found that both drugs produced statistically significant but modest improvements in satisfying sexual events relative to placebo, with neither clearly superior. Flibanserin carries an alcohol interaction warning and causes sedation; bremelanotide causes nausea and transient blood pressure elevation. Patient preference and tolerability, not efficacy differences, generally determine which drug is tried first.

Testosterone for HSDD (Off-Label)

Off-label testosterone (typically 0.5 to 2% compounded cream or gel, 0.3 to 0.5 mg/day) has the largest body of evidence for postmenopausal HSDD. A Cochrane review updated in 2019 (N=36 trials, 8,480 women) found that testosterone consistently improved sexual function scores across postmenopausal populations. The Global Consensus Position Statement on testosterone for women, endorsed by multiple major societies including the International Menopause Society and the Endocrine Society, supports its use for postmenopausal HSDD at physiologic premenopausal concentrations. For postmenopausal women specifically, testosterone may be a more evidence-supported starting point than bremelanotide.

Regulatory and Prescribing Considerations for Off-Label Use

Off-label prescribing is standard medical practice. The American Academy of Family Physicians and the FDA both affirm that licensed physicians may prescribe approved drugs for unapproved indications. The clinical and legal responsibility that comes with that latitude is real, though. For bremelanotide prescribed off-label, best practices include:

1. Documenting the diagnosis, including which DSM-5 or ICD-10 code applies.
2. Recording that on-label and other evidence-based options were discussed.
3. Obtaining explicit informed consent that includes the off-label status, the evidence grade, and the known side-effect profile.
4. Setting measurable treatment goals (for example, a target score on the FSFI desire subscale or a specific number of satisfying sexual events per month) and a defined re-evaluation point, typically at 8 to 12 weeks.

Telehealth prescribing of bremelanotide is permitted in most U.S. States as of mid-2025, but state-specific telehealth prescribing rules apply. A thorough asynchronous or synchronous evaluation that captures cardiovascular history, medication list, and sexual history is required before prescribing remotely.

Cost, Insurance Coverage, and Access

Bremelanotide (Vyleesi) has a retail list price of approximately $800 to $1,000 per autoinjector as of 2025. Insurance coverage is inconsistent. Many commercial plans do not cover it even for the approved indication, citing the modest effect sizes noted in the FDA label. AMAG Pharmaceuticals (now Palatin Technologies holds the drug patent; marketing rights were transferred) has offered a copay assistance program for commercially insured patients.

Compounded PT-141 from 503A compounding pharmacies is available at lower cost (typically $50 to $150 per vial) but carries no FDA oversight for purity, potency, or sterility. The FDA has not listed bremelanotide as a "bulk drug substance" permitted for compounding under section 503A of the Federal Food, Drug, and Cosmetic Act, which puts compounded versions in a legally and clinically ambiguous position. Women considering compounded PT-141 should be aware that the dose, sterility, and peptide authenticity cannot be guaranteed by the prescribing clinician.

Monitoring and Follow-Up Protocol

Women starting bremelanotide should have a documented baseline blood pressure measurement. A follow-up assessment at 8 to 12 weeks allows the clinician to evaluate:

• Change in FSFI desire subscale score (minimally clinically important difference: 1.2 points on the 6-point subscale)
• Change in FSDS-DAO distress score
• Tolerability (nausea frequency, injection-site reactions, any hyperpigmentation)
• Blood pressure if the patient is hypertensive at baseline

Women who report no meaningful improvement in desire or distress at 12 weeks should discontinue the drug. Continued prescribing in non-responders carries cost and side-effect burden without demonstrated benefit.